Ivonne Arias1, Daniel Herrera1, Wilson Bautista-Molano2,3, Juan Manuel Bello-Gualtero2,3, Juliette De Avila3, Fabián Salas-Cuestas2,3, Consuelo Romero-Sánchez4,5. 1. Instituto de Genética Humana, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia. 2. Rheumatology and Immunology Department / Clinical Immunology Group School of Medicine, Hospital Militar Central, Transversal 3ª # 49-00, Bogotá, 110231, Colombia. 3. Cellular and Molecular Immunology Group/InmuBo, Universidad El Bosque, Bogotá, Colombia. 4. Rheumatology and Immunology Department / Clinical Immunology Group School of Medicine, Hospital Militar Central, Transversal 3ª # 49-00, Bogotá, 110231, Colombia. romeromaria@unbosque.edu.co. 5. Cellular and Molecular Immunology Group/InmuBo, Universidad El Bosque, Bogotá, Colombia. romeromaria@unbosque.edu.co.
Abstract
OBJECTIVE: The evidence shows that previous infection with enteric pathogens is a requirement to develop pSpA. Based on our previous results, variances on regulation of SIgA might influence SpA activity; thus, the aim of this study was to correlate the levels of SIgA, IgA against some enteric bacteria, and IL-17, IL-21, and IL-6 with clinical features in a group of SpA patients. METHODS: Twenty-six pSpA, 20 nr-axSpA, 60 healthy volunteers (HV), and 34 patients with inflammatory bowel diseases (IBD) were included. All subjects were assessed to measure SIgA, total and specific IgA for enteric bacteria, and IL-17, IL-21, and IL-6 levels and clinical variables. For SpA patients, the diagnosis was verified 5 years after first evaluation to assess the risk of developing r-axSpA. RESULTS: SIgA levels were significantly higher in SpA patients than in HV and IBD (p < 0.0001 and p = 0.047, respectively). However, no differences for SIgA neither total IgA were found among the SpA subtypes (p = 0.624). Only IL-6 was higher in SpA than HV (p = 0.013). An inverse correlation was demonstrated for SIgA and BASFI (r: - 0.45; p = 0.003), BASDAI (r: - 0.39; p = 0.0123), ASDAS-CRP (r: - 0.37; p = 0.014), and ASDAS-ESR (r: - 0.45; p = 0.0021). There was no evidence of risk of developing r-axSpA in patients who previously showed high levels of serum antibodies. CONCLUSION: The results show that pSpA as well as nr-axSpA share a similar SIgA-intestinal involvement independently of a previous infection. This suggests that serum SIgA increases are evidence of subclinical intestinal compromise which could have influence on disease activity but not in this progression. Key Point • The levels of SIgA, IgA against some enteric bacteria, and IL-17, IL-21, and IL-6 are correlated with clinical features in a group of SpA patients.
OBJECTIVE: The evidence shows that previous infection with enteric pathogens is a requirement to develop pSpA. Based on our previous results, variances on regulation of SIgA might influence SpA activity; thus, the aim of this study was to correlate the levels of SIgA, IgA against some enteric bacteria, and IL-17, IL-21, and IL-6 with clinical features in a group of SpA patients. METHODS: Twenty-six pSpA, 20 nr-axSpA, 60 healthy volunteers (HV), and 34 patients with inflammatory bowel diseases (IBD) were included. All subjects were assessed to measure SIgA, total and specific IgA for enteric bacteria, and IL-17, IL-21, and IL-6 levels and clinical variables. For SpA patients, the diagnosis was verified 5 years after first evaluation to assess the risk of developing r-axSpA. RESULTS: SIgA levels were significantly higher in SpA patients than in HV and IBD (p < 0.0001 and p = 0.047, respectively). However, no differences for SIgA neither total IgA were found among the SpA subtypes (p = 0.624). Only IL-6 was higher in SpA than HV (p = 0.013). An inverse correlation was demonstrated for SIgA and BASFI (r: - 0.45; p = 0.003), BASDAI (r: - 0.39; p = 0.0123), ASDAS-CRP (r: - 0.37; p = 0.014), and ASDAS-ESR (r: - 0.45; p = 0.0021). There was no evidence of risk of developing r-axSpA in patients who previously showed high levels of serum antibodies. CONCLUSION: The results show that pSpA as well as nr-axSpA share a similar SIgA-intestinal involvement independently of a previous infection. This suggests that serum SIgA increases are evidence of subclinical intestinal compromise which could have influence on disease activity but not in this progression. Key Point • The levels of SIgA, IgA against some enteric bacteria, and IL-17, IL-21, and IL-6 are correlated with clinical features in a group of SpA patients.
Entities:
Keywords:
ASDAS; BASDAI; Intestinal disease; Secretory immunoglobulin A (SIgA); Spondyloarthritis
Authors: Danielle T Avery; Vanessa L Bryant; Cindy S Ma; Rene de Waal Malefyt; Stuart G Tangye Journal: J Immunol Date: 2008-08-01 Impact factor: 5.422
Authors: C Romero-Sanchez; Diego A Jaimes; J Londoño; J De Avila; Jaime E Castellanos; Juan M Bello; W Bautista; R Valle-Oñate Journal: Clin Exp Rheumatol Date: 2011-10-31 Impact factor: 4.473
Authors: M Rudwaleit; R Landewé; D van der Heijde; J Listing; J Brandt; J Braun; R Burgos-Vargas; E Collantes-Estevez; J Davis; B Dijkmans; M Dougados; P Emery; I E van der Horst-Bruinsma; R Inman; M A Khan; M Leirisalo-Repo; S van der Linden; W P Maksymowych; H Mielants; I Olivieri; R Sturrock; K de Vlam; J Sieper Journal: Ann Rheum Dis Date: 2009-03-17 Impact factor: 19.103
Authors: Fabián Salas-Cuestas; Wilson Bautista-Molano; Juan M Bello-Gualtero; Ivonne Arias; Diana Marcela Castillo; Lorena Chila-Moreno; Rafael Valle-Oñate; Daniel Herrera; Consuelo Romero-Sánchez Journal: Front Immunol Date: 2017-04-27 Impact factor: 7.561